tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Gout D006073 4 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Graves Disease D006111 6 associated lipids
Gynecomastia D006177 6 associated lipids
Hallucinations D006212 4 associated lipids
Hand Dermatoses D006229 5 associated lipids
Hand Injuries D006230 1 associated lipids
Headache D006261 4 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Schmidt LE et al. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients. 2003 Transplantation pmid:12883193
Sheiner PA et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. 1994 Transplantation pmid:7513099
Troppmann C et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. 2003 Transplantation pmid:12883205
Therapondos G et al. Cardiac hypertrophy in liver transplant recipients: tacrolimus, cyclosporine or both? 2003 Transplantation pmid:12883220
Gaynor JJ and Ciancio G The Importance of Using Serially Measured Tacrolimus Clearance Values, Especially During the Early Posttransplantation Period. 2018 Transplantation pmid:29271869
Andrades KM et al. Modulation of Candida albicans virulence by antirejection immunosuppressant drugs. 2013 Transplantation pmid:23380869
Ellis D et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. 1999 Transplantation pmid:10532541
Migita K et al. FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. 1999 Transplantation pmid:10532544
Takaya S et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. 1992 Transplantation pmid:1371195
Francavilla A et al. Inhibition of liver, kidney, and intestine regeneration by rapamycin. 1992 Transplantation pmid:1371198
Boleslawski E et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. 2004 Transplantation pmid:15223897
Reutzel-Selke A et al. Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors. 2003 Transplantation pmid:12811235
Molano RD et al. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. 2003 Transplantation pmid:12811239
Bilolo KK et al. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. 2003 Transplantation pmid:12811249
Trancassini M et al. Microbiologic investigation on patients with cystic fibrosis subjected to bilateral lung transplantation. 2001 Transplantation pmid:11707748
Waldman WJ et al. Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. 2001 Transplantation pmid:11707749
Miroux C et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. 2012 Transplantation pmid:22743548
Bierer BE et al. Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. 1990 Transplantation pmid:1694317
Eiras G et al. Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. 1990 Transplantation pmid:1694318
Tze WJ et al. In vitro effects of FK-506 on human and rat islets. 1990 Transplantation pmid:1694319
Morrissey PE et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. 1997 Transplantation pmid:9089224
Woodle ES et al. FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. 1993 Transplantation pmid:7504346
Jindal RM et al. Effect of deoxyspergualin on the endocrine function of the rat pancreas. 1993 Transplantation pmid:7504347
Gerlach UA et al. Intragraft and Systemic Immune Parameters Discriminating Between Rejection and Long-Term Graft Function in a Preclinical Model of Intestinal Transplantation. 2017 Transplantation pmid:27607529
de Sandes-Freitas TV et al. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus. 2015 Transplantation pmid:25929604
Jain A et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. 2001 Transplantation pmid:11579306
Sheiner PA et al. Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction. 1997 Transplantation pmid:9355846
Karlsson H and Nässberger L FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. 1997 Transplantation pmid:9355847
van Hooff JP Pneumocystis carinii pneumonia after renal transplantation. 1997 Transplantation pmid:9158038
Conrotto D et al. Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. 2006 Transplantation pmid:17060865
Reding R et al. Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. 1994 Transplantation pmid:7507272
Kitayama T et al. Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression. 2003 Transplantation pmid:12605126
Egidi MF and Gaber AO Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. 2003 Transplantation pmid:12605133
Watanabe M et al. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance. 2013 Transplantation pmid:23860082
Lufft V et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. 1996 Transplantation pmid:8779695
Burroughs TE et al. Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. 2009 Transplantation pmid:19667939
Jurcevic S et al. A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. 1998 Transplantation pmid:9603168
Kung L and Halloran PF Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. 2000 Transplantation pmid:10933159
Beatty PR et al. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. 1998 Transplantation pmid:9603175
Macphee IA et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. 2002 Transplantation pmid:12490779
Maes BD et al. Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. 1999 Transplantation pmid:10589943
Shapiro AM et al. Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. 2002 Transplantation pmid:12490784
Mehra MR et al. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. 2002 Transplantation pmid:12490790
Aulagnon F et al. Diarrhea after kidney transplantation: a new look at a frequent symptom. 2014 Transplantation pmid:25073040
Tokita D et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. 2008 Transplantation pmid:18301333
Niioka T et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. 2012 Transplantation pmid:23073468
Gruessner RW and Sharp HL Living-related intestinal transplantation: first report of a standardized surgical technique. 1997 Transplantation pmid:9415566
Ekberg H et al. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. 2009 Transplantation pmid:19424036
Swinnen LJ et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. 2008 Transplantation pmid:18645482
Wannhoff A et al. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. 2014 Transplantation pmid:25022236
Sureshkumar KK and Chopra B In search of an optimal induction agent in kidney transplantation. 2014 Transplantation pmid:24978038
Welberry Smith MP and Baker RJ The author's reply. 2014 Transplantation pmid:24978039
Sommerer C et al. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. 2010 Transplantation pmid:20463649
Froud T et al. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. 2008 Transplantation pmid:19104407
Tan HP et al. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. 2008 Transplantation pmid:19104412
Devlin J and Williams R Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants. European FK506 Liver Study Group. 1996 Transplantation pmid:8932266
Curran CF et al. Acute overdoses of tacrolimus. 1996 Transplantation pmid:8932293
de Fijter JW Tacrolimus dosing in mycophenolate-treated patients--can we get away with less? 2011 Transplantation pmid:21654351
Brunet M et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. 2006 Transplantation pmid:16495801
MacDonald AS Management strategies for nephrotoxicity. 2000 Transplantation pmid:10910262
Reyes J et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. 2000 Transplantation pmid:10910279
Fealy MJ et al. Association of down-regulation of cytokine activity with rat hind limb allograft survival. 1995 Transplantation pmid:7539555
Higgins RM et al. Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. 2000 Transplantation pmid:10836393
Garton T Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1. 2002 Transplantation pmid:12352898
Yamauchi A et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. 2002 Transplantation pmid:12352921
Ekser B et al. Hepatic function after genetically engineered pig liver transplantation in baboons. 2010 Transplantation pmid:20606605
Roberti I et al. Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. 1992 Transplantation pmid:1384182
van Boekel GA et al. Effect of mild diarrhea on tacrolimus exposure. 2012 Transplantation pmid:22955188
Langrehr JM et al. Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. 1992 Transplantation pmid:1384185
Woodle ES et al. Liver transplantation in the first three months of life. 1998 Transplantation pmid:9753340
McCarthy SA et al. The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes. 1992 Transplantation pmid:1384186
Radkowski M et al. Detection of hepatitis C virus replication in peripheral blood mononuclear cells after orthotopic liver transplantation. 1998 Transplantation pmid:9753352
Nakajima K et al. Prolongation of cardiac xenograft survival in rats treated with 15-deoxyspergualin alone and in combination with FK506. 1988 Transplantation pmid:2454521
Ciancio G et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. 2004 Transplantation pmid:14742989
Ciancio G et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. 2004 Transplantation pmid:14742990
van Hooff JP et al. Tacrolimus and posttransplant diabetes mellitus in renal transplantation. 2005 Transplantation pmid:15940032
Wang X et al. Immunosuppression with a combination of pg490-88 and a subtherapeutic dose of FK506 in a canine renal allograft model. 2005 Transplantation pmid:15940043
Gillard P et al. Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. 2014 Transplantation pmid:24770614
Bazerbachi F et al. Pancreas-after-kidney versus synchronous pancreas-kidney transplantation: comparison of intermediate-term results. 2013 Transplantation pmid:23183776
Günther M et al. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. 2001 Transplantation pmid:11233913
Murase N et al. Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. 1993 Transplantation pmid:7678353
Herold KC et al. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. 1993 Transplantation pmid:7678356
Holman MJ et al. FK506-associated thrombotic thrombocytopenic purpura. 1993 Transplantation pmid:7678357
Ekberg H et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. 2011 Transplantation pmid:21562449
Rezeig MA et al. Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. 1997 Transplantation pmid:9175820
Kuypers DR et al. Clinically relevant drug interaction between voriconazole and tacrolimus in a primary renal allograft recipient. 2006 Transplantation pmid:16794545
Hricik DE et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. 2003 Transplantation pmid:14508357
Foster RD et al. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade. 2003 Transplantation pmid:14508367
Mor E et al. Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. 1994 Transplantation pmid:7513098
Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. 2003 Apr-May TreatmentUpdate pmid:17216847
Kunz J and Hall MN Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. 1993 Trends Biochem. Sci. pmid:7694398
Cardenas ME et al. Signal-transduction cascades as targets for therapeutic intervention by natural products. 1998 Trends Biotechnol. pmid:9807840
Snyder SH et al. Neural actions of immunophilin ligands. 1998 Trends Pharmacol. Sci. pmid:9509898
Liu J FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. 1993 Trends Pharmacol. Sci. pmid:7692652
Chang JY et al. FK506 and rapamycin: novel pharmacological probes of the immune response. 1991 Trends Pharmacol. Sci. pmid:1710854
Sommerer C et al. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. 2016 Trials pmid:26888217
Nashan B et al. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. 2015 Trials pmid:25873064
Bajetta E et al. Merkel cell carcinoma after liver transplantation: a case report. 2007 May-Jun Tumori pmid:17679476
Vennarecci G et al. [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. 2003 Jul-Aug Tumori pmid:12903579
Tümgör G et al. A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. 2014 Turk J Gastroenterol pmid:25599790